Qu’apporte la réponse tumorale dans le cancer colorectal ?

摘要: Tumor size reduction after cancer treatment is evaluated by tumor response. It often the primary objective of phase II clinical trials. The WHO and RECIST criteria are now internationally recognized for quantification response in This literature review article focuses on interest measuring according to these terms benefit patients with metastatic colorectal (mCRC): metastasis resection, survival improving quality life. In mCRC initially resectable metastases, following preoperative chemotherapy an independent prognosis factor a way testing sensitivity regime; it allows and/or facilitates metastases resection. potentially obtaining allow secondary resection one objectives chemotherapy. non-resectable may provide individual control symptoms life favor benefit. Despite limitations criteria, no other morphological or functional radiological criterion has date achieved consensus up availability, reproducibility, sensitivity, specificity, relevance cost. Finally, although there high-level evidence, prognostic value therapeutic symptomatic advanced disease.